Thursday October 5, 1:30 pm Eastern Time
HOUSTON--(BUSINESS WIRE)--Oct. 5, 2000--Pathobiotek Diagnostics Inc. (OTCBB:PBTK - news; http://www.pathobiotek.com), a developer of products for the diagnosis and evaluation of treatment for multiple sclerosis (MS) and other immune disorders, announced the results from the preliminary data of the correlation study.
A correlation study began in July of this year to study the relationship of Luey (the bacterium discovered by Pathobiotek) and symptoms of multiple sclerosis (MS) and other immune disorders. Preliminary data is very promising. The first few MS samples showed over 100 times the Lueys per milliliter when compared to normals. The balance of the samples to be tested, over the next few months, is expected to support the preliminary data and if that happens, it should result in many benefits for Pathobiotek. This early data supports the data collected over the past eight years but with more sophisticated and accurate diagnostics.
According to a company official the full study has to be completed and the results analyzed but it looks very promising with the newly developed diagnostic tools. It is anticipated that the positive outcome of the study will improve business opportunities for Pathobiotek in the form of collaborative development agreements, license and royalty agreements. This is the type of data that strategic partners want to see and the better it is the better the revenue opportunity.
Safe Harbor for Forward-Looking Statements: Except for historical information
contained herein, the statements in this press release are forward-looking
statements that are made pursuant to the safe harbor provisions of the
Private Securities Reform Act of 1995. Forward-looking statements involve
known and unknown risks and uncertainties, which may cause the company's
actual results in future periods to differ materially from forecasted results.
These risks and uncertainties include, among other things, product price
volatility, product demand, market competition, risk inherent in the company's
domestic and international operations, imprecision in estimating product
reserves and the company's ability to replace and expand its holdings.
Pathobiotek Diagnostics Inc., Houston
Glinda Fortner, 713/939-1833 Ext. 300